Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Seeking Alpha / 4 hours ago 1 Views
Seeking Alpha / 4 hours ago 1 Views
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026
Comments